Why INSM Stock Is Advancing Today

Drug maker Insmed (INSM) is rising 6% today after it released on Friday afternoon its estimate of the revenue generated by its Arikayce drug in 2024. The company also provided 2025 sales guidance for Arikayce and reported that it would seek to launch a new drug in the third quarter of this year.

Arikayce is a treatment for a type of lung disease called Mycobacterium avium complex or MAC. The product is inhaled using a nebulizer. It was approved in 2018.

A laboratory technician in a safety suit analyzing and conducting a series of experiments.

Insmed’s Friday Announcements

The company reported that Arikayce generated about $363.7 million of sales last year, representing an increase of 19% versus 2023. That was slightly above the top of the company’s guidance range.

Insmed added that it expects to obtain $405 million to $425 million of revenue from the treatment in 2025.

Additionally, INSM stated that it would attempt to launch its brensocatib, a drug that’s supposed to treat bronchiectasis, in Q3. However, the drug has not yet been approved by the FDA, and the company indicated that it would only be able to meet its Q3 target if the agency grants the drug priority review and approves it.

The drug maker is looking to launch brensocatib in the EU, UK and Japan in 2026.

“We believe the upcoming clinical and commercial catalysts have the potential to redefine Insmed from a company that can serve approximately 30,000 patients today to one able to reach more than 2.5 million patients by the end of the decade,” CEO Will Lewis said in a statement.

While we acknowledge the potential of INSM, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than INSM but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ ALSO 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock

Disclosure: None. This article is originally published at Insider Monkey.